We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood Test Identifies People at Risk of Developing Blood Cancers

By LabMedica International staff writers
Posted on 28 Aug 2023
Print article
Image: The tool can identify individuals at risk of developing different myeloid leukaemias (Photo courtesy of 123RF)
Image: The tool can identify individuals at risk of developing different myeloid leukaemias (Photo courtesy of 123RF)

The myeloid neoplasms form a group of interconnected cancers encompassing acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Although treatments for these cancers have advanced in recent years, the majority of cases remain without a cure. Recent scientific discoveries have revealed that these cancers develop slowly over decades through the accumulation of DNA mutations in blood stem cells, which are responsible for normal blood formation. These mutations prompt these stem cells to grow faster than usual, and as additional mutations gather, they can lead to leukemia. Fortunately, while mutations promoting cell growth are prevalent, only a small subset of cases progresses to leukemia. Detecting these cases at an early stage could be vital in preventing the development of these cancers. Scientists have now developed a novel test to identify individuals at risk of developing acute myeloid leukemia and related cancers, years before their onset.

Researchers at the University of Cambridge (Cambridge, UK) along with their colleagues have introduced a new platform named 'MN-predict.' This platform empowers doctors and researchers to identify individuals at risk and devise new treatments to prevent the emergence of these potentially life-threatening cancers. The team examined data from over 400,000 individuals to create "MN-predict," a predictive tool capable of assessing the likelihood of developing blood cancers within a 10-15-year timeframe. This test involves patients providing a blood sample from which DNA is extracted and sequenced on a limited scale, along with basic blood cell counts. Armed with this information, the platform identifies those with a high risk of developing any of these cancers. Its application can be integrated into specialized clinics dedicated to leukemia prevention.

“We all know that prevention is better than cure, but it is not easy to prevent diseases like leukemia without knowing who is at risk,” said Professor George Vassiliou, senior author of the study. “MN-predict makes it possible to identify at-risk individuals, and we hope it can become an essential part of future leukemia prevention programs.”

Related Links:
University of Cambridge

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Multi-Channel Pipettor
BioPette Plus
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.